Integra LifeSciences Holdings Corporation today announced that it has completed the acquisition of DuraSeal® product lines from Covidien. Now, together with our DuraGen® family of grafts, Integra offers surgeons the largest portfolio of dural repair solutions.
Integra will provide complete 2014 guidance, including the financial impact of this acquisition, on its 2013 full year financial results conference call on February 25, 2014.
"The acquisition of the DuraSeal product line offers us a great opportunity to drive our Neurosurgery growth strategy, aimed at providing a broader set of solutions for surgical procedures in the head," said Robert Davis, President of Integra's U.S. Neurosurgery division. "The Neurosurgery product portfolio will now have products in both dural grafting and the very different indication of dural sealing. DuraSeal is the first-to-market dural sealant approved for use in both the cranium and spine."
"In addition to its strategic value, DuraSeal will add scale and increase profitability by every measure without introducing new complexity into our structure," said Peter Arduini, Integra's President and Chief Executive Officer. "We believe that it will create significant value for our customers, employees and shareholders alike."